The US Supreme Court’s decision to overturn Roe v. Wade will generate a minefield of legal and criminal implications for healthcare providers, according to this Healthcare Dive article. McDermott Partners Stacey Callaghan and David Gacioch offer insight into what these restrictive state laws could mean for providers.
State Abortion Bans Signal Chaos for Providers
By Stacey Callaghan and David Quinn Gacioch on July 8, 2022
Stacey CallaghanStacey Callaghan counsels healthcare entities, healthcare technology companies, data companies, and private equity entities as they navigate transactional, regulatory, and compliance issues. She focuses on assisting clients on matters including data privacy and protection requirements under HIPAA and other privacy laws, data breach investigations and compliance, and data sharing, licensing, and de-identification arrangements. Stacey also assists clients in developing telemedicine strategies and documenting agreements given the evolving digital health regulatory landscape. Read Stacey L. Callaghan's full bio.
David Quinn GaciochDavid Quinn (Dave) Gacioch focuses his practice on litigation and enforcement defense, primarily related to the US healthcare sector. Dave counsels hospitals, health systems, physician practices, and other providers, along with payors, private equity sponsors, pharmaceutical and medical device manufacturers, and others involved in the US healthcare system, on compliance and risk mitigation issues. He conducts internal investigations for clients, and represents them in government investigations, enforcement actions, and civil and criminal litigation, including class actions. Read David Gacioch's full bio.
Related Posts
- Fired for Having an Abortion? Unlikely, but It’s Complicated
- Abortion Questions Swirl Over Health Lawyers in Post-Roe World
- Workers’ Abortion Privacy at Risk as Texas Targets Employer Aid
- Complex Patchwork of Laws Await Companies Offering Out-of-State Abortion Travel
- What Should GCs Know About the Abortion Landscape?
BLOG EDITORS
STAY CONNECTED
TOPICS
ARCHIVES
RECENT POSTS
- New EO Targets Prescription Drug Costs – and Drug Manufacturers, Hospitals, and Health Centers
- Understanding and Navigating Compliance With NIH Grant DEI Policies
- 5 Trends in Health Plan Regulations to Watch in New Trump Administration
- IRS Announces 2026 Limits for Health Savings Accounts, High-Deductible Health Plans, and Excepted Benefit HRAs
- DOJ Secures Its First-Ever Conviction in a Criminal Antitrust Labor Market Trial
